Big Pharma and researchers are sharpening their focus on AI to speed drug discovery. But the path to fully AI-driven drug discovery faces substantial hurdles, according to Adityo Prakash, CEO of Verseon. “When it comes to drug discovery, AI has a data problem with which the pharmaceutical industry has not yet come to terms,” he…

Researchers at Google’s DeepMind AI team have used AI to create advanced sorting algorithms, which although not specifically designed for drug discovery, could potentially benefit the field. Published in Nature, DeepMind’s latest work demonstrates the use of deep reinforcement learning to create more efficient routines for sorting and hashing. These algorithms find use in various…

At the Nvidia GTC 2023, DeepMind’s Founder and CEO, Demis Hassabis, provided an in-depth look into the seismic potential of their protein folding AI system, AlphaFold. Hassabis said AlphaFold was a contender for the organization’s “biggest project to date.” Hassabis noted that DeepMind’s AlphaFold has made strides in addressing the protein folding problem, a challenge…

Alphabet subsidiary DeepMind has announced that its AI system AlphaFold has predicted the structure of more than 200 million proteins, representing almost every known cataloged protein. In addition, AlphaFold and its partner, the EMBL‘s European Bioinformatics Institute, announced that the recent release expanded the database by more than 200 fold, from almost 1 million to…

A Google-owned lab has accurately predicted protein structures, potentially paving the way toward advances in drug discovery. London-based DeepMind lab has developed a deep-learning program known as AlphaFold that bested roughly 100 efforts to predict protein structures in a contest known as Critical Assessment of Structure Prediction (CASP). Such proteins are found within the cells…